Lindsay to serve as co-chair for the Patient-Centered Outcomes Research Institute’s (PCORI) Advisory Panel on Rare Diseases, one of five multi-stakeholder advisory panels.
Phase 3 trial involves hospitalized patients with moderate to severe disease
Congratulations to ICTS investigator, Jonathan Bath, MD, assistant professor of surgery at the University of Missouri-Columbia School of Medicine and medical student Danielle Kinsey on their honorable mention in the NCATS Rare Diseases Are Not Rare 2020 Challenge .
Researchers at Washington University School of Medicine in St. Louis have received a pair of grants totaling $11.3 million to study genetic and environmental factors that contribute to developmental disabilities and to find new ways to improve the lives of children and adults affected by such disabilities.
Pieces of four antibodies (turquoise) attach to a protein from influenza B virus (gray) in the colorized cryo-electron microscopy reconstruction. Researchers at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai have identified two antibodies that protect mice against lethal infections of influenza B virus.
Trying to manage funding a lab while running a lab can be challenging for even the most experienced investigator. For Hong Chen, PhD, assistant professor of biomedical engineering at the McKelvey School of Engineering at Washington University in St. Louis and of radiation oncology at the School of Medicine, the ICTS provided invaluable assistance on […]
The Infectious Disease Clinical Research Unit at Washington University School of Medicine has launched the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the AIDS Clinical Trials Group. The school’s Infectious Disease Clinical Research Unit is one of 25 initial sites conducting ACTIV-2, which includes both phase 2 and phase […]
The ability of The Foundation for Barnes-Jewish Hospital to rapidly provide support for scientific research to understand the biology of this infection, and to speed the development of countermeasures—testing, treatments and vaccines—was critical in accelerating research in our laboratories and for our patients. William G. Powderly, the Dr. J. William Campbell Professor of Medicine, co-director, […]